Our i-Biomarker CaDx international patent (pending) – a non-invasive Multi-Cancer Early Detection and Diagnosis test working on 32 cancer types with 99-100% accuracy - was
awarded with “Excellency Diploma and Gold Medal” at ProInvent 2023 the International Salon of Scientific Research, Innovation, and Inventions.
Thank you to everyone who has been a part of our journey, and we can't wait to continue pushing the boundaries of AI in the fight against
MiWear - Transforming Healthcare with MIR Spectroscopy
Problem: Current healthcare relies on reactive models, often leading to late diagnosis and severe consequences for conditions like metabolic syndrome.
Innovation: MiWear revolutionizes healthcare with affordable Mid-Infrared Spectroscopy. We detect biomarkers in the skin, enabling continuous monitoring and informed healthcare decisions.
Consortium: Our diverse team, including experts in spectroscopy, biomedicine, AI, and business, collaborates to make this revolutionary technology accessible to all, with a focus on societal and economic impact.
Click on the image on the left to view the poster.
Our company recently presented the abstract "i-Biomarker™ CaDx Detects 99-100% of Lung Cancers" at the International Conference on Cancer Research and Clinical Trials (CRCT-2023) hosted in Dubai. The abstract will be published soon in the British Journal of Cancer Research with a permanent DOI number!
Check out the attached presentation and discover more about our groundbreaking research!
We're pleased to announce that we've been invited to contribute a chapter to the upcoming book "Molecular Diagnostics of Cancer." with our proposal titled "i-Biomarker - Multi Cancer Early Detection as a Data Science with AI Problem"
We are thrilled to have the opportunity to share our groundbreaking research and expertise with a wider audience.
An European Project aiming to Optimise and predict antidepressant efficacy for patient with major depressive disorders using multi-omics analysis and AI-predictive tools.
31 January 2023
The Kick-off meeting of the European project OPADE was held at the EBRIS Foundation (EUROPEAN BIOMEDICAL RESEARCH INSTITUTE OF SALERNO) on 23-24th January. The project will have a duration of 54 months, ending on 31 May 2027.
The project general objective is to identify key biomarkers that support the decision-making process of the healthcare providers. The project focuses on the microbiota – brain -axis which plays a major role in mental health and in particular Major depression disorder. Through clinical investigations, the consortium partners will study the combination between genetics, epigenetics, microbiome and inflammatory networks.
OPADE project is 100% funded by the European Union (Horizon Europe Grant Agreement 101095436). Scientifically coordinated by EBRIS Foundation, it integrates a consortium of research centres, hospitals and enterprises from ten different countries. The consortium is completed by The CEINGE BIOTECNOLOGIE AVANZATE SCARL (Italy), PERSEUS BIOMICS (Belgium), FUNDACIO EURECAT (Spain), ARTIFICIAL INTELLIGENCE EXPERT SRL (Romania), MAMA HEALTH TECHNOLOGIES GMBH (Germany), PROTOBIOS OU (Estonia), CEPHALGO (France), BIOKERALTY RESEARCH INSTITUTE AIE (Spain), FUNDACION UNIVERSITARIA SANITAS (Colombia), UNIVERSITA DEGLI STUDI DI SIENA (Italy), STICHTING UNIVERSITAIRE EN ALGEMENE KINDER - EN JEUGDPSYCHIATRIE NOORD-NEDERLAND (The Netherlands), FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE GIRONA DOCTOR JOSEP TRUETA (Spain) and ISTANBUL MEDIPOL UNIVERSITESI (Turkey).
During this meeting researchers from the different organizations discussed the key issues to be addressed during the first year and the administrative procedures to ensure the success of this innovative project.
The Seal of Excellence (SoE) certificate recognises the value of the proposal and helps other funding bodies take advantage of the high quality Commission evaluation process.
AIE was named 2nd in profit in Romania's top for SMEs focused on Innovation and Research activities
Our company is among the top disruptors in the innovative medical startups in CEE region. The report was officially published on June 14, 2022 during the international „AI in Health” Conference.
AIE is part of the consortium for OPADE project. The project won the HORIZON-HLTH-2022-TOOL-11 Call in August and will begin in early 2023.
On 18 July 2022 AIE recieved the GO for the 2nd stage of the EIC Accelerator project VINCI. Winning this 6M grant & investment will help us bring the Breast Cancer Early Detection Test to the market.
The invention supporting our Multi-Cancer Early Detection test "METHOD AND SYSTEM FOR MULTI-CANCER MANAGEMENT IN SUBJECT" is Patent Pending since 4th of July 2022.
Indian Journal of Cancer
Dr. Alexandru Floares, President of Solutions of Artificial Intelligence Applications (SAIA) and CEO of Artificial Intelligence Expert and OncoPredict, Romania opines that “Statistical Methods are still dominant even though there is a paradigm shift in the use of artificial intelligence in oncology. It is not a smooth evolution from traditional statistical methods to artificial intelligence.”
Our CEO, Dr. Alexandru Floares, was an invited speaker at a 3-day workshop organized by the Pontifical Academy for Life on Ethics and Artificial Intelligence (AI). He spoke to Vatican Radio on the potential for larger strides in the field of oncology and medical research through the efficiency that AI provides.
EU CORDIS: News article
The AI-MICADIS project developed and tested an extremely accurate, non-invasive tool for early detection and diagnosis of multiple cancer types.
Our company participated in our national Start-ups Competition, Startarium, organized by Impact Hub Bucharest.
There we managed to reach the final, where AIE was placed in the top 10 start-ups from Romania in 2019.
Cluj-Napoca | Str. Alexandru Vlahuta, LAMA C/45 | Romania, CJ 400310